ViiV Healthcare

viivhealthcare.com

A global specialist HIV company, 100% focused on researching and delivering new medicines and improving access to care for people living with HIV.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES OVER BICTEGRAVIR IN US & CANADA

Pharmaceutical Executive | February 12, 2018

news image

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada. The United States case is filed in the US District Court for the District of Delaware and the patent is US patent No. 8,129,385. The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282....

Read More

VIIV’S LONG-ACTING TWO-DRUG HIV REGIMEN HITS TARGETS

ViiV Healthcare | July 25, 2017

news image

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who ...

Read More

US APPROVES VIIV’S TWO-DRUG HIV REGIMEN

ViiV Healthcare | November 22, 2017

news image

ViiV Healthcare’s Juluca has been green-lighted in the US as the first two-drug regimen for some patients with HIV. Juluca is comprised of ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor....

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES OVER BICTEGRAVIR IN US & CANADA

Pharmaceutical Executive | February 12, 2018

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada. The United States case is filed in the US District Court for the District of Delaware and the patent is US patent No. 8,129,385. The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282....

Read More
news image

VIIV’S LONG-ACTING TWO-DRUG HIV REGIMEN HITS TARGETS

ViiV Healthcare | July 25, 2017

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who ...

Read More
news image

US APPROVES VIIV’S TWO-DRUG HIV REGIMEN

ViiV Healthcare | November 22, 2017

ViiV Healthcare’s Juluca has been green-lighted in the US as the first two-drug regimen for some patients with HIV. Juluca is comprised of ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor....

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us